live
attenu
measl
viru
mv
vaccin
impress
record
safeti
efficaci
abil
induc
lifelong
immun
measl
infect
use
revers
genet
technolog
negativestrand
rna
virus
rescu
clone
dna
technolog
allow
insert
exogen
gene
encod
foreign
antigen
mv
genom
way
express
mv
vaccin
strain
without
affect
viru
structur
propag
cell
target
recombin
virus
rescu
clone
cdna
induc
immun
respons
measl
viru
clone
antigen
toler
mv
gene
insert
make
attract
flexibl
vector
system
especi
broad
immun
respons
requir
fact
measl
replic
strictli
occur
cytoplasm
infect
cell
without
dna
intermedi
import
biosafeti
implic
add
attract
mv
vector
articl
report
characterist
report
gene
express
gfp
lacz
cat
biochem
biophys
immunolog
properti
recombin
mv
express
heterolog
antigen
simian
immunogefici
viru
siv
modern
approach
vaccinolog
immunolog
lead
discoveri
number
antigen
potenti
allow
address
complex
diseas
aid
cancer
malaria
administ
appropri
way
therefor
establish
potent
antigen
deliveri
system
becam
essenti
progress
field
use
live
attenu
viral
vector
appear
promis
especi
sinc
multipl
antigen
effici
present
immun
system
attenu
measl
viru
mv
vaccin
repres
number
essenti
featur
develop
candid
prophylact
therapeut
vaccin
among
featur
safeti
immunogen
cost
effect
recombin
vaccin
mv
belong
genu
morbilliviru
famili
paramyxovirida
envelop
viru
long
nonseg
rna
genom
neg
polar
ender
peebl
inocul
primari
human
kidney
cell
blood
david
edmonston
child
measl
result
edmonston
strain
mv
subsequ
adapt
growth
varieti
cell
line
adapt
chicken
embryo
chick
embryo
fibroblast
cef
andor
dog
kidney
cell
human
diploid
cell
produc
attenu
edmonston
b
zagreb
ez
aikc
seed
edmonstonb
licens
first
mv
vaccin
howev
reactogen
abandon
passag
edmonston
b
cef
produc
attenu
moraten
vaccin
today
schwarzmoraten
aikc
ez
vaccin
commonli
use
mv
vaccin
induc
lifelong
immun
singl
two
lowdos
inject
persist
antibodi
cell
shown
long
year
vaccin
mv
vaccin
easili
produc
larg
scale
countri
distribut
low
cost
attenu
mv
genom
result
advantag
combin
numer
mutat
vaccin
stabl
revers
pathogen
never
observ
regard
safeti
mv
replic
exclus
cytoplasm
rule
possibl
integr
host
dna
characterist
make
live
attenu
mv
vaccin
attract
candid
use
multival
vaccin
vector
revers
genet
system
mv
establish
allow
rescu
infecti
mv
clone
cdna
addit
mvspecifc
transcript
unit
contain
multipl
clone
site
introduc
mv
antigenom
ie
cdna
sequenc
allow
addit
simultan
express
sever
exogen
gene
gene
hepat
b
viru
hbv
simian
human
immunodefici
virus
siv
hiv
mump
viru
mv
west
nile
viru
wnv
human
insert
express
differ
loci
mv
genom
show
multipl
marker
gene
code
chloramphenicol
acetyltransferas
cat
green
fluoresc
protein
gfp
betagalactosidas
bgal
express
simultan
progeni
addit
recombin
mv
express
singl
multipl
antigen
siv
induc
strong
endur
humor
immun
respons
experiment
anim
cell
maintain
monolay
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
fc
vero
cell
african
green
monkey
kidney
fc
mg
per
millilitr
stabli
transfect
human
embryon
kidney
cell
cell
construct
describ
report
deriv
plasmid
p
mv
plasmid
sever
vector
plasmid
gener
bear
addit
transcript
unit
contain
suitabl
restrict
site
easi
exchang
orf
site
includ
bsshii
snabi
aatii
mlui
nrui
flank
gfp
orf
gfp
orf
thu
swap
transgen
insert
deriv
pathogen
specif
uniqu
restrict
site
also
uniqu
extrem
transgen
care
taken
final
construct
total
number
nucleotid
recombin
antigenom
mv
sequenc
multipl
six
fulllength
mv
plasmid
contain
three
exogen
marker
gene
gener
insert
green
fluoresc
protein
gfp
upstream
n
gene
posit
betagalactosidas
lacz
p
gene
posit
chloramphenicol
acetyltransferas
cat
h
l
gene
posit
fig
gener
multireport
plasmid
basic
origin
three
independ
plasmid
express
egfp
lacz
cat
saciipaci
segment
contain
lacz
plasmid
p
mplaczv
express
lacz
posit
exchang
saciipaci
segment
p
megfpnv
plasmid
give
rise
intermedi
p
megfpnlaczpv
final
triport
plasmid
gener
replac
pacinoti
fragment
contain
cat
gene
plasmid
p
mhcatv
express
cat
posit
fig
schemat
represent
modif
introduc
antigenom
p
mv
measl
viru
gfp
lacz
cat
insert
simultan
antigenom
p
mv
plasmid
see
section
siv
gene
env
pol
gag
insert
report
previous
plasmid
contain
env
gene
posit
gag
gene
posit
p
p
digest
saciipaci
saciipaci
insert
p
replac
p
gener
p
gagsiv
arrow
indic
insert
posit
addit
transcript
unit
rna
polymeras
promotor
hepat
delta
ribozym
pacinoti
fragment
p
megfpnlaczpv
clone
procedur
plasmid
carri
siv
gene
carri
basic
describ
wang
et
al
pcr
amplif
perform
use
proof
read
pfu
dna
polymeras
stratagen
pcr
amplif
sivgag
env
gene
done
specif
primer
flank
snabi
bsshii
insert
posit
respect
fig
gener
two
differ
fulllength
plasmid
plasmid
p
p
fig
digest
sacii
paci
fragment
saciipaci
p
swap
p
result
plasmid
p
gagsiv
recombin
virus
rescu
accord
radeck
et
al
slightli
modifi
protocol
rescu
virus
serial
passag
time
vero
cell
seed
plate
infect
standard
recombin
mv
moi
pfucel
monolay
fulli
infect
supernat
cultur
use
infect
subsequ
vero
cell
monolay
test
transgen
express
stabil
virus
passag
use
character
express
immunofluoresc
western
blot
essenti
describ
visual
express
protein
infect
cell
coverslip
fix
paraformaldehyd
pb
permeabil
pb
wash
block
solut
pb
contain
bsa
h
stain
specif
antibodi
monoclon
antisiv
polyclon
antisivgag
antibodi
use
dilut
vv
follow
fitc
conjug
goat
antimous
anti
rabbit
serum
respect
cell
analyz
confoc
microscop
imag
system
consist
leica
invert
microscop
dm
irb
leica
true
confoc
scanner
tc
nt
silicon
graphic
workstat
imag
record
use
leica
pl
apo
oil
pl
apo
oil
immers
object
system
equip
argonkrypton
mix
ga
laser
imag
process
done
silicon
graphic
workstat
use
imari
bitplan
ag
zurich
switzerland
multichannel
imag
process
softwar
specialis
confoc
microscopi
imag
purif
mv
recombin
mv
perform
essenti
accord
spielhof
et
al
supernat
approxim
pfu
mv
recombin
mv
infect
cell
first
clarifi
centrifug
g
min
layer
cushion
ml
sucros
tne
mm
tri
ph
mm
nacl
mm
edta
centrifug
rpm
min
rotor
sucros
interphas
ml
taken
dilut
sucros
appli
top
ml
sucros
step
gradient
follow
centrifug
rotor
rpm
h
equilibrium
gradient
prepar
use
auto
densiflow
labconco
usa
control
gradient
contain
viru
run
parallel
measur
fluctuat
densiti
fraction
approxim
l
collect
densiti
measur
weigh
twice
l
fraction
similarli
densiti
control
fraction
determin
less
differ
densiti
among
correspond
fraction
gradient
detect
protein
content
fraction
analyz
sdspage
follow
immunoblot
sucros
gradient
purifi
mv
rmvsiv
virus
pellet
ultracentrifug
rpmmin
h
resuspend
l
pb
ph
l
place
grid
neg
stain
immunogold
stain
polymorph
mv
viru
virion
size
nm
contain
ribonucleoprotein
rnp
visual
immunogold
stain
grid
treat
antimvh
monoclon
antibodi
wash
pb
incub
min
room
temperatur
dilut
nm
colloid
gold
particl
coat
protein
aurion
netherland
free
protein
agold
complex
wash
away
accord
standard
protocol
genet
modifi
mice
suscept
mv
infect
use
immun
experi
mice
express
human
gene
humanlik
tissu
specif
addit
target
mutat
inactiv
interferon
receptor
type
anim
kept
optim
hygien
condit
immun
week
age
immun
perform
intraperiton
ip
pfu
recombin
mv
two
inject
week
noninfect
mice
serv
control
uv
inactiv
mv
use
control
determin
effect
viru
replic
activ
immun
respons
total
rna
mous
spleen
extract
previous
describ
revers
transcript
minusstrand
primer
ttataacaatgatggagggtaggc
hybrid
last
nucleotid
n
mrna
use
realtim
quantit
taqman
pcr
base
primer
pair
gggtaccatcctagcccaaatt
cgaatcagctgccgtgtct
amplifi
base
n
mrna
molecular
beacon
famcgcaaaggcggttacggcccdabcyl
fam
serv
report
fluorochrom
acid
dabcyl
serv
quencher
perform
accord
protocol
supplier
perkinelm
appli
biosystem
briefli
l
reaction
mixtur
contain
l
cdna
rt
reaction
l
taqman
pcr
master
mix
perkinelm
nm
concentr
primer
nm
molecular
beacon
one
cycl
denatur
c
min
appli
follow
cycl
amplif
c
c
min
pcr
carri
spectrophotometr
thermal
cycler
abi
prism
sequenc
detect
system
perkinelm
monitor
chang
fluoresc
spectrum
molecular
beacon
fam
reaction
tube
cours
reaction
result
realtim
analysi
realtim
pcr
quantif
standard
curv
gener
triplic
sampl
purifi
mv
n
rna
transcrib
vitro
briefli
mv
n
genecontain
plasmid
p
mnpcat
linear
stui
transcrib
vitro
use
rna
polymeras
digest
dna
templat
rnasefre
dnase
roch
basel
switzerland
gener
mv
n
rna
transcript
purifi
analyz
agaros
gel
follow
determin
concentr
spectrophotometri
linear
copi
number
rang
copi
equival
per
reaction
dilut
taken
rtpcr
amplif
detect
correspond
threshold
cycl
rang
correspond
mv
n
rna
copi
equival
per
rtpcr
respect
determin
viral
rna
load
express
mv
n
rna
copi
number
per
g
total
rna
calcul
mv
n
rna
copi
per
averag
cell
done
consid
splenic
cell
contain
approxim
g
total
rna
presenc
mvspecif
antibodi
sera
immun
mice
per
group
determin
elisa
use
microwel
plate
coat
measl
viru
eia
bulk
atcc
igg
antibodi
detect
virion
zurich
protein
dilut
gml
carbon
buffer
ph
lwell
ad
microtit
plate
plate
incub
overnight
c
wash
tween
pt
incub
pt
mlwell
bovin
serum
albumin
min
c
wash
pt
serial
twofold
dilut
test
sera
ad
lwell
plate
incub
min
c
plate
wash
pt
incub
l
per
well
goat
antimous
igg
gamma
hrp
klp
dilut
tween
min
c
plate
wash
pt
incub
l
opd
ophenylendiamin
fluka
reaction
stop
min
plate
read
microelisa
reader
wavelength
nm
read
higher
threefold
neg
control
score
posit
reaction
antisiv
env
igg
antibodi
titer
sera
immun
mice
determin
elisa
assay
briefli
plate
coat
siv
antigen
kind
obtain
aid
research
refer
reagent
program
divis
aid
niaid
nih
siv
catalog
number
dilut
carbon
buffer
ph
concentr
ngwell
plate
incub
overnight
c
wash
pt
subsequ
unspeci
interact
block
defat
milk
dissolv
pt
hour
c
well
wash
pt
plate
consecut
incub
variou
dilut
mous
sera
start
follow
serial
twofold
dilut
peroxidaseconjug
goat
antimous
igg
klp
opd
substrat
ophenylendiamin
fluka
optic
densiti
valu
measur
nm
valu
cutoff
background
level
mean
valu
sera
mv
immun
mice
multipli
factor
consid
posit
titer
depict
reciproc
enddilut
shown
earlier
larg
transgen
kb
stabli
express
mv
vector
multipl
insert
simultan
express
multipl
gene
appear
challeng
fig
show
three
report
gene
gfp
lacz
cat
activ
express
singl
mv
construct
total
size
insert
genet
materi
around
mvgenom
restrict
viru
assembl
gene
express
sinc
report
gene
cytosol
express
possibl
express
may
hamper
viru
assembl
growth
usual
take
place
cell
surfac
therefor
determin
efficaci
express
heterolog
antigen
siv
env
transmemberan
protein
gag
cytosol
protein
fig
indic
express
env
green
gag
red
syncytia
stabil
express
determin
passag
vero
cell
demonstr
stabil
protein
express
singl
transgen
pol
previous
report
use
control
doubl
transgen
env
gag
fig
result
support
use
mv
vector
express
singl
multipl
gene
concern
envelop
protein
transmembran
domain
foreign
virus
case
sivenv
might
integr
lipid
envelop
matur
recombin
viru
thu
affect
tropism
viru
therefor
cellfre
viru
particl
recombin
mvsiv
express
either
env
alon
env
gag
infect
vero
cell
cultur
sediment
equilibrium
sucros
gradient
ultracentrifug
determin
protein
content
fraction
gradient
fraction
analyz
western
blot
probe
monoclon
sivenv
mixtur
monoclon
antibodi
mv
p
separ
experi
use
monoclon
antimvh
antibodi
mv
addit
infect
gradient
fraction
densiti
determin
fig
mv
infecti
particl
detect
fraction
gradient
subsequ
mv
p
compon
infecti
particl
also
detect
fraction
fig
sivenv
protein
detect
top
fraction
gradient
fig
fraction
like
due
membran
associ
env
clarifi
centrifug
upon
express
sivenv
gag
togeth
slight
shift
sivenv
heavier
fraction
observ
fig
howev
envgag
complex
coloc
mv
particl
fact
presenc
gag
env
desiti
shift
heavier
env
gag
coexpress
indic
antigen
may
form
complex
viruslik
particl
vlp
higher
densiti
env
alon
fig
determin
buoyant
densiti
particl
show
differ
recombin
mv
standard
mv
gml
summari
demonstr
sivenv
protein
incorpor
mv
lipid
envelop
structur
modif
made
virion
addit
env
gag
envgag
gene
viral
genom
rna
order
visual
envelop
protein
local
distribut
well
potenti
incorpor
sivenv
mv
envelop
corrobor
biochem
data
cellfre
mv
recombin
mvsiv
examin
immunoelectron
microscopi
virus
immunolabel
indirect
reaction
employ
antimvh
monoclon
antibodi
monoclon
antisivenv
antibodi
follow
protein
coat
nm
nm
colloid
gold
antih
antibodi
reactiv
envelop
larg
pleomorph
mv
virion
fig
show
typic
electrondens
rnp
structur
accumul
insid
hcontain
envelop
contrast
antisiv
antibodi
local
surfac
recombin
mv
particl
gold
partic
sporad
observ
away
viru
fig
interestingli
vlp
observ
prepar
recombin
mv
express
sivenv
gag
gagsiv
fig
vlp
observ
recombin
express
sivenv
alon
shown
diamet
roundshap
structur
varri
nm
lightli
coat
gold
particl
suggest
siv
env
like
present
particl
sinc
phenomenon
occur
upon
coexpress
sivenv
gag
conclud
presenc
vlp
prepar
due
envgag
associ
result
accord
previou
find
differ
lab
taqman
technolog
use
quantifi
vivo
replic
recombin
virus
ten
mice
suscept
measl
infect
immun
ip
pfu
mv
spleen
collect
interv
day
day
post
immun
fig
isol
total
rna
revers
transcrib
use
minusstrand
primer
hybrid
last
nucleotid
n
mrna
segment
base
cdna
amplifi
pcr
see
section
c
antimv
antibodi
measur
standard
elisa
assay
antisiv
env
antibodi
measur
enddilut
see
section
siv
env
elisa
sera
five
mice
pool
coat
plate
treat
describ
section
valu
cutoff
background
level
mean
valu
sera
mv
immun
mice
neg
control
multipli
factor
consid
posit
titer
depict
reciproc
enddilut
standard
quantif
vitro
transcrib
mv
n
rna
use
result
triplic
experi
show
mv
replic
highest
day
post
immun
copi
per
g
total
rna
gradual
decreas
reach
three
log
reduct
day
fig
determin
whether
rmvsiv
virus
replic
fashion
similar
experi
done
spleen
sampl
withdrawn
day
post
immun
mice
immun
mv
rmvsiv
gagsiv
show
replic
virus
compar
level
fig
result
indic
vivo
mv
recombin
mv
replic
similar
kinet
although
doubl
recombin
gagsiv
show
slightli
lower
copi
number
n
mrna
significantli
affect
induct
immun
respons
see
express
sivenv
gag
document
earlier
recombin
virus
express
env
postion
recombin
viru
express
simultan
env
posit
gag
posit
also
use
immun
transgen
mice
immun
respons
toward
mv
sivenv
determin
elisa
mv
specif
antibodi
respons
induc
standard
mv
vaccin
rmvsiv
compar
week
post
immun
fig
uv
inactiv
mv
induc
margin
level
antibodi
titer
fade
away
quickli
indic
replic
mv
rmv
necessari
induc
high
persist
immun
repons
three
rmvsiv
vector
initi
induct
igg
sivenv
protein
appear
differ
week
post
immun
antibodi
level
reach
rather
similar
end
point
post
immun
fig
high
earli
week
antienv
antibodi
titer
induc
doubl
recombin
gagsiv
recombin
mv
express
env
posit
appear
elicit
lowest
initi
antisivenv
antibodi
titer
week
post
immun
remark
view
fact
doubl
recombin
grew
slightli
lower
titer
two
recombin
fig
observ
antisivenv
antibodi
titer
remain
rather
high
declin
slowli
week
similar
antimv
antibodi
therefor
longev
humor
immun
respons
foreign
antigen
appear
follow
kinet
similar
observ
mv
specif
antibodi
respons
fig
result
describ
report
demonstr
nonseg
neg
strand
rna
measl
viru
use
vector
stabli
express
heterolog
gene
singli
combin
ii
exclud
foreign
antigen
shown
sivenv
incorpor
envelop
viral
progeni
iii
singl
multipl
gene
express
induc
longliv
humor
immun
respons
vector
mv
insert
geneproduct
siv
due
helic
structur
mv
nucleocapsid
appear
definit
size
limit
insert
foreign
genet
materi
size
insert
exceed
kb
wherea
valu
establish
report
gene
insert
similar
size
encod
siv
antigen
also
success
achiev
although
genet
heavili
load
virus
propag
slightli
slower
standard
mv
result
end
viral
titer
similar
even
gratifi
observ
serial
passag
total
amplif
around
fold
high
genet
stabil
rmv
ensur
express
differ
gene
includ
pathogen
deriv
heterolog
gene
larg
insert
may
toler
mainli
view
littl
constraint
genom
size
pleomorph
viru
helic
nucleocapsid
believ
stabil
gene
express
like
due
factor
tight
rnp
structur
adher
mvgenom
rule
six
defin
calain
roux
slow
elong
rate
rna
replic
may
allow
intern
proofread
control
viral
polymeras
fact
mv
live
attenu
vaccin
strain
genet
engin
live
recombin
mv
care
analyz
eg
confirm
sequenc
ident
vector
moiti
correspond
sequenc
origin
vaccin
strain
inde
regulatori
hurdl
may
aris
essenti
biolog
properti
genet
modifi
organ
gmo
modifi
complet
chang
also
appli
recombin
mv
importantli
maintain
fuction
target
recombin
vaccin
viru
ie
vivo
tropism
maintain
analyz
incorpor
foreign
transmembran
protein
sivenv
cellfre
recombin
mv
biochem
immunoelectron
microscopi
could
demonstr
siv
env
exclud
envelop
mv
therefor
induct
immun
respons
toward
sivenv
due
vivo
express
transgen
replic
recombin
mv
target
cell
experiment
anim
report
fact
result
present
demonstr
first
time
replic
recombin
mv
transgen
mice
mv
vector
carri
either
singl
multipl
gene
differ
genom
locat
find
variou
direct
medic
applic
specif
develop
prophylact
multival
vaccin
interestingli
sinc
mv
effici
infect
profession
antigen
present
cell
macrophag
particularli
dendrit
cell
mvbase
vector
deliv
foreign
cargo
directli
effici
antigen
present
cell
therefor
wide
experi
mv
measl
vaccin
favour
use
mv
vector
model
develop
novel
multival
vaccin
includ
hiv
mv
hiv
sever
properti
common
sinc
infect
monocyt
macrophag
dendrit
cell
respect
mv
vector
target
hiv
protein
compart
hiv
may
provid
advantag
altern
vector
system
particularli
induct
danger
signal
addit
replic
live
attenu
mv
advantag
capac
induc
longlast
immun
also
demonstr
recombin
mv
express
siv
antigen
induc
significantli
high
longliv
antibodi
respons
mv
sivenv
antigen
therefor
capac
induc
strong
long
last
protect
immun
liveattenu
mv
express
appropri
hiv
gene
could
potenti
serv
pediatr
vaccin
protect
simultan
measl
aid
immunogen
induc
system
like
due
quantit
level
express
present
antigen
cell
infect
live
recombin
mv
ii
proper
effici
present
immun
system
immunogen
recombin
mv
express
heterolog
antigen
betag
hbv
hiv
wnv
test
transgen
mice
recombin
mv
vector
express
betag
significantli
activ
cellular
immun
respons
immun
respons
hbv
surfac
core
antigen
test
intranas
intraperiton
inocul
reveal
high
level
antimv
antibodi
reason
amount
antibodi
hbv
rmv
vector
express
secret
form
eglycoprotein
wnv
strain
surfac
antigen
sarscov
induc
neutral
antibodi
wnv
sarscov
linig
et
al
submit
furthermor
immun
chimer
mvvsv
envelop
swap
mv
f
h
vesicular
stomat
viru
g
vsvg
protect
immunocomprom
mice
lethal
dose
vsv
importantli
demonstr
preexist
antibodi
mv
block
immunogen
potenti
recombin
viru
abl
induc
antihiv
antibodi
prevaccin
mice
macaqu
provid
two
inject
administ
last
featur
highli
relev
potenti
widspread
use
mv
vaccin
vector
inde
presenc
antimv
immun
nearli
entir
adult
human
popul
would
seem
restrict
use
mv
recombin
infant
alreadi
worthi
goal
event
howev
larg
vaccin
studi
show
revaccin
alreadi
immun
individu
result
boost
antimv
antibodi
suggest
attenu
live
vaccin
replic
express
protein
spite
preexist
immun
studi
cellmedi
immun
infant
given
measl
vaccin
first
year
life
show
presenc
matern
antimeasl
antibodi
preclud
induct
antimeasl
cellular
respons
respons
effici
boost
circumst
one
might
hope
abl
vaccin
adult
foreign
antigen
rmv
inde
demonstr
earlier
preclin
model
lorin
et
al
result
laboratori
linig
et
al
publish
howev
remain
seen
whether
mv
vector
induc
immun
carrier
protein
alreadi
immun
individu
evalu
safeti
mv
vector
phase
ii
clinic
studi
trial
aim
defin
appropri
dose
rmv
ii
demonstr
accept
reactogen
profil
recombin
virus
confirm
absenc
vivo
viru
shed
vaccine
final
recombin
mv
vaccin
intend
immun
human
simultan
measl
addit
infecti
diseas
must
deriv
approv
strain
mv
vaccin
purpos
clinic
approv
mv
vaccin
edmonston
zagreb
ez
vaccin
strain
berna
biotech
ltd
wide
use
europ
asia
africa
whose
safeti
also
demonstr
aerosol
vaccin
south
africa
mexico
use
